Combination Study of AZD5069 and Enzalutamide.

  • End date
    Oct 1, 2023
  • participants needed
  • sponsor
    Institute of Cancer Research, United Kingdom
Updated on 11 May 2021


ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC). The investigators will be investigating the safety and toxicity of the combination.


The purpose of this study is to find out the side effects and safety of a combination of the CXCR2 antagonist, AZD5069 in combination with the androgen receptor antagonist, enzalutamide in patients with metastatic castration resistant prostate cancer and to determine the most appropriate dose of this combination. During the phase I study, patients will receive AZD5069 orally twice daily (BD) in combination with enzalutamide at 160mg orally once daily continuously. The starting dose of AZD5069 will be 40mg BD (dose level 1): other doses to be evaluated will include 80mg BD (dose level 2), 120mg BD (dose level 3), 160mg BD (dose level 4) and 320mg BD (dose level 5) in order to determine the MTD and RP2D to take forward to a Phase II reversal of resistance cohort. Intermediate dose levels such as 240mg BD may also be evaluated. During dose levels 1 to 4, patients will start with AZD5069 monotherapy for two weeks before commencing the combination. At all other dose levels, the two agents will be started concurrently. In addition, if agreed by the SRC, intermediate dose levels such as 240 mg taken BD will be explored. The Phase II part of the study will evaluate the optimized dose/schedule identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.

In the Phase I part of the study, the AZD5069 is started first and will be taken twice daily as an oral tablet at Cycle 1, Day -14 for 14 days. Two weeks later on Cycle 1 Day 1, patients will start taking 160mg enzalutamide once a day in addition to the AZD5069. The starting dose of AZD5069 will be 40mg taken orally twice daily with single dose escalations to 80mg, 120mg and 160mg taken orally twice daily to determine the MTD to take forward to a Phase II reversal of resistance cohort.

The Phase II reversal of enzalutamide resistance study will explore whether the addition of AZD5069 to enzalutamide reverses resistance to enzalutamide alone. In the phase II reversal of enzalutamide resistance study patients will start taking the AZD5069 at the dose established in the Phase I safety run in part of the study in combination with 160mg of enzalutamide once a day and at the same time from Cycle 1 Day 1 onwards.

If the MTD of AZD5069 is greater than 160 mg BD, two different dose levels may be taken forward to the phase II study to determine efficacy. Only patients who have experienced disease progression after at least 12 weeks of treatment with enzalutamide, apalutamide or darolutamide will be eligible for this trial. Those patients who progressed on enzalutamide, apalutamide or darolutamide (at least 12 weeks of therapy) greater than 6 months prior to starting the IMP will enter the Phase II enzalutamide resistance run in cohort to confirm resistance to enzalutamide; once progression on enzalutamide is confirmed they will enter the Phase II reversal of enzalutamide resistance cohort.

Up to approximately 86 patients will be enrolled into this phase I/II trial, with up to 36 patients in the phase I safety run in cohort depending on number of patients required to determine the RP2D and up to 50 patients in the phase II study. We predict around 50% of these patients will enter the phase II enzalutamide resistance run in cohort first. The anticipated accrual rate for this trial is 3-6 patients per month across 4 centres.

Condition Metastatic Castration Resistant Prostate Cancer
Treatment AZD5069, Enzalutamide 40 MG
Clinical Study IdentifierNCT03177187
SponsorInstitute of Cancer Research, United Kingdom
Last Modified on11 May 2021


How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note